BRIEF-Merck And Gilead Provide Update On Phase 3 Keynote-D46/Evoke-03 Study

Merck
Gilead Sciences

Merck

MRK

0.00

Gilead Sciences

GILD

0.00

June 8 (Reuters) - Gilead Sciences, Inc GILD.O:

  • MERCK AND GILEAD PROVIDE UPDATE ON PHASE 3 KEYNOTE-D46/EVOKE-03 STUDY

  • GILEAD: STUDY DID NOT ACHIEVE STATISTICAL SIGNIFICANCE FOR PROGRESSION-FREE OR OVERALL SURVIVAL

  • GILEAD: DISCONTINUATION OF PHASE 3 KEYNOTE-D46/EVOKE-03 STUDY INVESTIGATING GILEAD'S TRODELVY IN COMBINATION WITH KEYTRUDA

  • GILEAD: NO CHANGES TO ONGOING TRODELVY OR MERCK STUDIES

  • GILEAD: SAFETY PROFILE OF TRODELVY IN COMBINATION WITH KEYTRUDA CONSISTENT WITH KNOWN SAFETY OF EACH AGENT

  • GILEAD: NO NEW SAFETY SIGNALS WERE IDENTIFIED WITH TRODELVY IN COMBINATION WITH KEYTRUDA

Source text: ID:nBwbWZmRza

Further company coverage: GILD.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.